New Strain of Humanized Mice Enhances Antibody Drug Development

Immunocan Introduces ImmuMab® HKL Mouse

Immunocan has successfully developed a new strain of humanized mouse called ImmuMab® HKL. This mouse strain contains human immunoglobulin variable region genes, making it a significant advancement in antibody drug development.

These genetically engineered mice can produce fully human antibodies, potentially improving the success rate of developing effective antibody therapies.

The Importance of Lambda Light Chains

In the human immune system, about 35% of antibodies are lambda light chain antibodies (λ-antibodies). However, traditional mice used in antibody generation have a much lower proportion of λ-antibodies.

The ImmuMab® HKL mouse increases the diversity of potential antibodies, enhancing the chances of finding effective therapeutic candidates.

How It Works

Using proprietary technology, Immunocan replaced the mouse's immunoglobulin variable regions with human versions, totaling 3.2 Mb. This makes the ImmuMab® HKL mouse the most human-like antibody-producing mouse available.

This innovation helps expand the repertoire of λ-antibodies, which can target different parts of an antigen compared to other light chain antibodies.

Advancing Antibody Drug Discovery

With more diverse antibodies, researchers are less likely to miss potential therapeutic candidates during the early stages of drug development. This increase in diversity also means more options for tackling complex diseases.

By producing human-like antibodies, the ImmuMab® HKL mouse can potentially reduce the risk of early exclusion of promising drug candidates.

Other Platforms by Immunocan

Alongside ImmuMab® HKL, Immunocan has developed other innovative platforms such as ImmuMab® HK for kappa light chain antibodies and ImmuMab Heavy® for heavy-chain-only antibodies. These platforms diversify the types of human antibodies available for research.

Future developments include increasing the range of species used, such as alpaca-derived antibodies and rabbit heavy-chain-only antibodies, providing even more tools for researchers.

The Goal: Better Therapeutic Options

Immunocan aims to provide researchers with more effective tools for developing new treatments. This increased variety in antibody generation could lead to better therapies for patients.

By working with global research partners, Immunocan hopes to accelerate the development of safer, more effective therapeutic products.

For more information about Immunocan and their innovative technology, visit their website or contact them directly.